A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

Inclusion Criteria Concurrent Medication: Allowed: * Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and herpes simplex. Patients must have: * Asymptomatic HIV infection. * CD4 count \> 300 cells/mm3. * No prior AIDS-defining illness or current constitutional symptoms of HIV disease. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current history of cardiac disease, including patients who exhibit long QT syndrome on EKG screening. * Active malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of the cervix. Concurrent Medication: Excluded: * Antiretroviral agents, including ddI, ddC, and AZT. * Immunosuppressive agents. * Investigational HIV drugs/therapies including vaccines. * Interferon. * Steroids (other than topical). * Hematopoietins. * Megestrol acetate. * Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly. * Cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Radiation therapy. Patients with the following prior conditions are excluded: * Prior history of cardiac disease. * History of agranulocytosis or severe (grade 3) drug-induced neutropenia or documented abnormalities in granulocyte number or function. Prior Medication: Excluded: * AZT, ddI, and ddC within 14 days prior to study entry. * Prior cytotoxic chemotherapy. Prior Treatment: Excluded: * Radiation therapy (including electron beam irradiation) within 30 days prior to study entry. Active illicit drug abuse.